SAN FRANCISCO, California (May 20, 2025) — Grove AI, a company advancing the next generation of clinical trials with artificial intelligence, today shared that its AI PRM™ platform and Digital Staff™ agent, Grace, have accelerated participant engagement and recruitment for over 50 leading Phase II and III clinical trials. These trials span diverse therapeutic areas, including cardiometabolic, neurology, psychiatry, gastroenterology, dermatology, pain, infectious disease, and more.

Over the past year, Grove AI has supported more than 100,000 participants in finding their best-fit trials by optimizing prescreening workflows through advanced AI-powered data analytics, patient-trial matching, and personalized engagement via calls, texts, and emails. Grove AI's technology enables precise prescreening at scale, helping research teams advance clinical trial enrollment timelines while maintaining rigorous research standards.

Grove AI continues to expand across additional therapeutic areas and deepen the data and automation capabilities of its platforms to accelerate more workflows across clinical trial participant recruitment and engagement. In partnership with leading sponsors, CROs, sites, central IRBs, participants, and industry experts, Grove AI is setting a new standard for efficient, scalable, and compliant participant engagement—empowering research teams to elevate participant experiences and drive digital transformation amid the growing complexity of modern clinical trials.

Grove AI will be at BIO 2025 in Boston from June 16 to 29, 2025, to share insights on the transformative role of generative AI in clinical trial recruitment and engagement.